LeserbriefKommentar
ALK -Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.0750 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Paul G Kemps und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Histiocytosis. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Anaplastic Lymphoma KinaseHistiocytosisFemaleHumansMaleBiopsyCase Reports as Topic
Substanzen
ALK protein, humanAnaplastic Lymphoma Kinase
Autor:innen und Institutionen
- Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Department of Pathology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.
Zitieren
APA
Kemps, P. G., Picarsic, J. L., & Emile, J. F. (2024). ALK -Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.0750
Vancouver
Kemps PG, Picarsic JL, Emile JF. ALK -Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.0750
BibTeX
@article{Kemps2024,
author = {Kemps, Paul G and Picarsic, Jennifer L and Emile, Jean-François},
title = {ALK -Positive Histiocytosis—A Distinct Histiocytic Entity Deserving Recognition},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.0750}
}
EUVIMED